Effects of <i>CYP2D6*4</i> polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder.

Mikhail S Zastrozhin Valentin Yurievich SkryabinAleksey PetukhovElena PankratenkoSergei PozdniakovValentina IvanchenkoDenis HoryaevRoman VlasovskihEvgeny BryunDmitry Sychev

Published in: Journal of psychopharmacology (Oxford, England) (2022)

The effect of <i>CYP2D6*4</i> genetic polymorphism on the efficacy profile of paroxetine was demonstrated in a group of 267 patients with depressive disorder.

Keyphrases

end stage renal disease
alcohol use disorder
ejection fraction
bipolar disorder
newly diagnosed
chronic kidney disease
stress induced
prognostic factors
copy number